Predictors of Recurrence for High Risk Endometrial Cancer Patients

High-risk Endometrial Cancer Clinical Trial

Official title:

Predictors of Recurrence for High Risk Endometrial Cancer Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04412902
• Other study ID #: 109053-E
• Status: Completed
• Start date: April 25, 2020
• Est. completion date: November 25, 2020

Study information

• Verified date: April 2020
• Source: Far Eastern Memorial Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study will analyze whether there is any difference in recurrence and survival rates among the patients who received different adjuvant therapies.

Description:

The incidence of endometrial cancer is gradually increasing nowaday. The postoperative treatment of high-risk endometrial cancer is also inconsistent. Besides, the recurrence of high-risk endometrial cancer is high.The investigators retrospective study will analyze the factors associated with recurrence of endometrial cancer, especially for different adjuvant therapies.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 92
• Est. completion date: November 25, 2020
• Est. primary completion date: October 25, 2020
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

• All patients with high risk stage I endometrial cancer and all patients with stage II and stage III endometrial cancer and who underwent therapy in Far Eastern Memorial Hospital from 2009/01/01~2019/09/17.

Exclusion Criteria:

• Patients with stage I endometrial cancer do not have high risk factors.

Related Conditions & MeSH terms

• Endometrial Neoplasms
• High-risk Endometrial Cancer
• Recurrence

Intervention

Drug:
• adjuvant therapy
Adjuvant chemotherapy and/or radiotherapy

Locations

Country	Name	City	State
Taiwan	Department of Obstetrics and Gynecology, Far-Eastern Memorial Hospital	Banqiao	New Taipei

Sponsors (1)

Lead Sponsor	Collaborator
Far Eastern Memorial Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Factors affecting overall survival	Factors affecting overall survival	10 years
Secondary	Factors affecting progression-free survival	Factors affecting progression-free survival	10 years